Results 31 to 40 of about 46,090 (276)

GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer [PDF]

PeerJ, 2022
Background Pancreatic ductal adenocarcinoma (PDAC) has the worst five-year overall survival rate among all cancer types. Acquired chemoresistance is considered one of the main reasons for this dismal prognosis, and the mechanism of chemoresistance is ...
Chen Chen, Binfeng Wu, Mingge Wang, Jinghua Chen, Zhaohui Huang, Jin-Song Shi   +5 more
doaj   +2 more sources

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1

Molecular Oncology, 2022
Patients with advanced bladder cancer are generally treated with a combination of chemotherapeutics, including gemcitabine, but the effect is limited due to acquisition of drug resistance. Thus, in this study, we investigated the mechanism of gemcitabine
Motoki Tamai, Shuichi Tatarano, Shunsuke Okamura, Wataru Fukumoto, Issei Kawakami, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Masaya Yonemori, Yasutoshi Yamada, Masayuki Nakagawa, Hideki Enokida, Hirofumi Yoshino   +12 more
doaj   +1 more source

Gemcitabine in Bone Sarcoma Resistant to Doxorubicin‐BasedChemotherapy [PDF]

Sarcoma, 2000
Subjects and Methods: Seven patients with progressive localized or metastatic chemo‐resistant osteosarcoma were treated by gemcitabine.The protocol included gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest.
Merimsky, Ofer, Meller, Isaac, Kollender, Yehuda, Issakov, Josephine, Flusser, Gideon, Inbar, Moshe   +5 more
openaire   +2 more sources

Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis

Cell Death and Disease, 2021
Gemcitabine is the first-line chemotherapy drug for cholangiocarcinoma (CCA), but acquired resistance has been frequently observed in CCA patients. To search for potential long noncoding RNAs (lncRNAs) involved in gemcitabine resistance, two gemcitabine ...
Min Lu, Xinglei Qin, Yajun Zhou, Gang Li, Zhaoyang Liu, Xiwen Geng, Haodi Yue   +6 more
doaj   +1 more source

PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer

Experimental and Molecular Medicine, 2020
Pancreatic cancer: Exploring a pathway to drug resistance A cell membrane protein called PROM2 promotes the resistance of pancreatic cancer to the anti-cancer drug gemcitabine, suggesting PROM2 and the molecular signaling pathway it stimulates could be ...
Wenbin Li, Yue Zhu, Kelin Zhang, Xianhuan Yu, Haoming Lin, Wenrui Wu, Yaorong Peng, Jian Sun   +7 more
doaj   +1 more source

Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway. [PDF]

PLoS ONE, 2016
Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs.
Zhen-Hua Wu, Chen Lin, Ming-Ming Liu, Jian Zhang, Zhong-Hua Tao, Xi-Chun Hu   +5 more
doaj   +1 more source

Gemcitabine for relapsed or resistant lymphoma

Annals of Oncology, 2000
Gemcitabine therapy has not been widely assessed in the treatment of hematological malignancies. We have examined the efficacy and safety of gemcitabine in patients with relapsed or resistant lymphoma.Gemcitabine (1 g/m2) was given weekly for 7 consecutive weeks, followed by a week off treatment.
D G, Savage, S A, Rule, M, Tighe, T J, Garrett, M W, Oster, R T, Lee, J, Ruiz, D, Heitjan, M L, Keohan, M, Flamm, S A, Johnson   +10 more
openaire   +2 more sources

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Naomi Walsh, Martin Clynes, Rizwan Sheikh, Sheikh, Rizwan, O'Connor, Robert A., Robert O’Connor, Ray McDermott, O'Connor, Robert, Clynes, Martin, Walsh, Naomi, McDermott, Ray   +10 more
core   +1 more source

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Understanding cisplatin resistance using cellular models [PDF]

, 2007
Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, M, Davey, Mary W., Davey, Mary W, Stordal, B, Britta Stordal, Mary Davey, Stordal, Britta   +6 more
core   +1 more source